Treatment of Recurrent and Persistent Non-Gonococcal Urethritis
For recurrent and persistent NGU in adult males who were compliant with initial therapy and reinfection is excluded, treat with metronidazole or tinidazole 2g single dose PLUS azithromycin 1g single dose (if not used initially), while awaiting testing results for Trichomonas vaginalis and Mycoplasma genitalium. 1
Critical First Step: Confirm Objective Urethritis
Before initiating any antimicrobial therapy for recurrent/persistent cases, you must document objective signs of urethritis 1:
- Urethral discharge on examination
- ≥5 polymorphonuclear leukocytes per high-power field on urethral smear
- Positive leukocyte esterase test on first-void urine, OR
- ≥10 WBC per high-power field on microscopic examination of first-void urine
Common pitfall: Symptoms alone without objective evidence are NOT sufficient grounds for retreatment 1. Extending antimicrobials in symptomatic patients without objective signs has not demonstrated value.
Algorithmic Approach to Recurrent/Persistent NGU
Step 1: Rule Out Reinfection and Non-Compliance
If the patient was not compliant with initial treatment OR was reexposed to an untreated partner, simply retreat with the initial regimen 1.
Step 2: For Compliant Patients Without Reexposure
Obtain diagnostic testing for:
- Trichomonas vaginalis (urethral swab, first-void urine, or semen for culture or NAAT)
- Mycoplasma genitalium (if available)
- Retest for Chlamydia trachomatis and Neisseria gonorrhoeae
While awaiting results, the CDC guideline recommends 1:
Recommended empiric regimen:
- Metronidazole 2g orally single dose OR Tinidazole 2g orally single dose
- PLUS
- Azithromycin 1g orally single dose (only if azithromycin was not used for the initial episode)
Step 3: Pathogen-Specific Considerations
For Mycoplasma genitalium:
- Persistent urethritis after doxycycline may indicate doxycycline-resistant U. urealyticum or M. genitalium 1
- Moxifloxacin 400mg orally once daily for 7 days is highly effective against M. genitalium 1, 2
- However, recent evidence suggests azithromycin resistance is emerging in M. genitalium, and neither azithromycin 1g nor doxycycline achieves >90% cure rates for this organism 3
For men with low probability of T. vaginalis (e.g., men who have sex with men):
- Unlikely to benefit from metronidazole/tinidazole addition 1
Step 4: Alternative Approach Based on Initial Therapy
If the above regimen fails or based on clinical judgment 2:
If doxycycline was first-line:
- Azithromycin (extended 5-day regimen) PLUS metronidazole 400-500mg twice daily for 5-7 days
If azithromycin was first-line:
- Doxycycline 100mg twice daily for 7 days PLUS metronidazole, OR
- Moxifloxacin 400mg once daily for 7-14 days
Important Caveats and Pitfalls
Consider Chronic Prostatitis/Chronic Pelvic Pain Syndrome
Be alert for 1:
- Persistent perineal, penile, or pelvic pain
- Irritative voiding symptoms
- Pain during/after ejaculation
- New-onset premature ejaculation lasting >3 months
These may indicate chronic prostatitis rather than persistent urethritis. A four-glass Meares-Stamey test may help localize pathogens to the prostate 1. Longer courses (4-6 weeks) of erythromycin have shown benefit in men with prostatic inflammation 4.
Partner Management is Essential
- All sex partners within preceding 60 days should be evaluated, tested, and empirically treated with a chlamydia-effective regimen 1
- Patients must abstain from intercourse until both partners complete treatment
- Reinfection from untreated partners is a major cause of apparent treatment failure
Testing Considerations
- Test of cure for M. genitalium should be collected no earlier than 3 weeks after treatment initiation 2
- Routine test of cure is not recommended for chlamydia/gonorrhea unless symptoms persist or noncompliance/reinfection suspected 1
- However, repeat testing at 3-6 months is recommended due to high reinfection rates
Resistance Concerns
The evidence increasingly suggests that azithromycin single-dose therapy may promote macrolide resistance in M. genitalium 2, 3. This is driving recommendations away from azithromycin as universal first-line therapy, though it remains in current CDC guidelines from 2010. Newer guidelines emphasize testing for M. genitalium and targeted therapy to preserve antibiotic effectiveness.